23 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 NEWS beet sugar, BENEO’s filler-binder is non-synthetic and peroxidefree. In addition to aligning with modern consumer needs, it also provides formulators with a stable, consistent, and reliable excipient solution. Proven performance in modern granulation In recent internal trials, galenIQ™ delivered impressive results across key metrics for twin screw granulation (TSG). It showed excellent compactability and produced high-strength tablets (>1.8 MPa) while maintaining rapid disintegration – a desired combination in continuous manufacturing. These attributes make galenIQ™ a particularly strong performer for TSG lines when stability, throughput, and formulation flexibility are essential. “galenIQ™ sets a new benchmark in excipient functionality. Unlike traditional binders, the isomaltbased excipient showed lower sensitivity to concentration levels. Formulators benefit from greater process control and more consistent product quality. This combination of reliability and performance makes galenIQ™ a strong choice for manufacturers seeking both efficiency in production and confidence in regulatory compliance,” says Dr Maj-Britt Cepok, Head of Pharma at BENEO. Discover galenIQ™ at Stand 8.0L70 Meet the BENEO team during the show and discover why galenIQ™ is the granulation binder of choice for modern manufacturing. Experience new data, application samples, and expert insights that show how this excipient performs in granulation processes – all while enhancing patient compliance. Don’t miss the chance to see how galenIQ™ can elevate your formulations and streamline your processes. Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a recognized leader in continuous process intensification, today announced a partnership to advance the development of multipurpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment in an industrial setting. The Microinnova equipment is designed to offer greater flexibility, easier scalability, enhanced efficiency and sustainable practices in active ingredient production. Together, the companies are aiming at faster process development, simple transition from lab to large-scale manufacturing, and ultimately decreased time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova. “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multipurpose manufacturing.” Hovione and Microinnova partner to advance modular flow chemistry for multi-purpose manufacturing
RkJQdWJsaXNoZXIy MjY2OTA4MA==